Monthly
US$200
Billed every month
Sign in to subscribeBaricitinib Tablets
Matched- Active ingredients (original)
- BARICITINIB
- Dosage form (original)
- TABLET
- Route (original)
- ORAL
Read these limits
- US patent expiration does not establish Chinese patent expiration. Dates here come from the US Orange Book; Chinese patent status needs separate checking.
- The Orange Book lists holder-submitted patents and does not cover all related patents.
- “Unmatched” means no English ingredient-name counterpart in the Chinese official-name sources loaded here; it does not mean no Chinese approval or filing. A zero count means a Chinese name is matched but no records were found in the loaded source. Source dates appear below.
- This page contains no sales or market-size data and cannot establish development value.
- Names on unmatched rows are the original FDA Orange Book names, without Chinese translation. The same ingredient may have a different generic name in China.
US-approved products
Application numbers, product numbers and original fields are retained. Marketing status is shown as listed in the source.
Earliest approval2018/05/31
ANDA applications2
RLD applicantELI LILLY AND CO
Currently marketed products: 6 · Counts FDA prescription and OTC marketing categories as listed; discontinued or unknown categories are excluded.
| Application / product number | Brand name (original) | Applicant (original) | Dosage form (original) | Route (original) | Strength (original) | Earliest approval | RLD / RS | Marketing status (original) | Official source |
|---|---|---|---|---|---|---|---|---|---|
| A217542-001 | BARICITINIB | AUROBINDO PHARMA LTD | TABLET | ORAL | BARICITINIB: 1MG | 2024/07/22 | N / N | DISCONTINUED | openFDA ↗ |
| A217542-002 | BARICITINIB | AUROBINDO PHARMA LTD | TABLET | ORAL | BARICITINIB: 2MG | 2024/07/22 | N / N | DISCONTINUED | openFDA ↗ |
| A217585-001 | OLUMIANT | MSN LABORATORIES PRIVATE LTD | TABLET | ORAL | BARICITINIB: 1MG | 2025/08/08 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A217585-002 | OLUMIANT | MSN LABORATORIES PRIVATE LTD | TABLET | ORAL | BARICITINIB: 2MG | 2025/08/08 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| A217585-003 | OLUMIANT | MSN LABORATORIES PRIVATE LTD | TABLET | ORAL | BARICITINIB: 4MG | 2025/08/08 | N / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N207924-001 | OLUMIANT | ELI LILLY AND CO | TABLET | ORAL | BARICITINIB: 2MG | 2018/05/31 | Y / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N207924-002 | OLUMIANT | ELI LILLY AND CO | TABLET | ORAL | BARICITINIB: 1MG | 2019/10/08 | Y / N | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
| N207924-003 | OLUMIANT | ELI LILLY AND CO | TABLET | ORAL | BARICITINIB: 4MG | 2022/05/10 | Y / Y | HUMAN PRESCRIPTION DRUG | openFDA ↗ |
Listed US patents
*PED rows, substance/product flags, use codes and delisting-request flags are retained without determining legal effect.
Latest listed patent expiration2032/11/30
Substance patent expiration (DS flag)2032/05/31
This column includes only source rows explicitly flagged DS. A PED row without that flag is not assigned one by this site.
| Application / product number | Patent number | Listed expiration | Substance / product flags | Use code | Delisting request | Official source |
|---|---|---|---|---|---|---|
| N207924-001 | 11045474 | 2032/11/30 | — / — | U-3372 | — | openFDA ↗ |
| N207924-001 | 11806555 | 2031/11/02 | — / — | U-3500 | — | openFDA ↗ |
| N207924-001 | 8158616 | 2032/05/31 | Y / Y | — | — | openFDA ↗ |
| N207924-001 | 8420629 | 2029/03/10 | — / — | U-247 | — | openFDA ↗ |
| N207924-001 | 9089574 | 2032/11/30 | — / — | U-3372 | — | openFDA ↗ |
| N207924-001 | 9737469 | 2031/11/02 | — / — | U-3500 | — | openFDA ↗ |
| N207924-002 | 11045474 | 2032/11/30 | — / — | U-3372 | — | openFDA ↗ |
| N207924-002 | 11806555 | 2031/11/02 | — / — | U-3500 | — | openFDA ↗ |
| N207924-002 | 8158616 | 2032/05/31 | Y / Y | — | — | openFDA ↗ |
| N207924-002 | 8420629 | 2029/03/10 | — / — | U-247 | — | openFDA ↗ |
| N207924-002 | 9089574 | 2032/11/30 | — / — | U-3372 | — | openFDA ↗ |
| N207924-002 | 9737469 | 2031/11/02 | — / — | U-3500 | — | openFDA ↗ |
| N207924-003 | 11045474 | 2032/11/30 | — / — | U-3372 | — | openFDA ↗ |
| N207924-003 | 11806555 | 2031/11/02 | — / — | U-3500 | — | openFDA ↗ |
| N207924-003 | 8158616 | 2032/05/31 | Y / Y | — | — | openFDA ↗ |
| N207924-003 | 9089574 | 2032/11/30 | — / — | U-3372 | — | openFDA ↗ |
| N207924-003 | 9737469 | 2031/11/02 | — / — | U-3500 | — | openFDA ↗ |
Exclusivity source records
FDA exclusivity code list ↗Latest exclusivity expiration: —
| Application / product number | Exclusivity code | Listed expiration | Official source |
|---|---|---|---|
| Not listed | |||
Chinese record details
Chinese product landscape ↗The four-zero filter applies only to matched rows: catalog holders, NHSA approval numbers, applications under review, and companies filing generics this year. Unmatched rows have no Chinese counts. Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Catalog holders 9
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Guangzhou Lv Shi Zi Pharmaceutical Co., Ltd. romanized | 国药准字H202648892mg | 2026/06/17 | Official source ↗ |
| Guangzhou Lv Shi Zi Pharmaceutical Co., Ltd. romanized | 国药准字H202648884mg | 2026/06/17 | Official source ↗ |
| Jiangsu Deyuan Pharmaceutical Co.,Ltd. | 国药准字H202642452mg | 2026/05/07 | Official source ↗ |
| Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized | 国药准字H202564324mg | 2025/12/30 | Official source ↗ |
| Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized | 国药准字H202564332mg | 2025/12/30 | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563182mg | 2025/12/16 | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563174mg | 2025/12/16 | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | 2025/11/25 | Official source ↗ |
| Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | 国药准字H20255895See source | 2025/11/12 | Official source ↗ |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H20255470See source | 2025/09/09 | Official source ↗ |
| Nanjing Li Bo Wei Pharmaceutical Co., Ltd. romanized | 国药准字H202341882mg | 2023/09/28 | Official source ↗ |
| Beijing Wan Hui Shuang He Pharma Co., Ltd. romanized | 国药准字H202662442mg | 2026/10/13 | Official source ↗ |
NHSA approval numbers 13
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Guangzhou Lv Shi Zi Pharmaceutical Co., Ltd. romanized | 国药准字H202648884mg | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563174mg | — | Official source ↗ |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H20255470See source | — | Official source ↗ |
| Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized | 国药准字H202564332mg | — | Official source ↗ |
| Jiangsu Deyuan Pharmaceutical Co.,Ltd. | 国药准字H202642452mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20190039See source | — | Official source ↗ |
| Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | 国药准字H20255895See source | — | Official source ↗ |
| Nanjing Li Bo Wei Pharmaceutical Co., Ltd. romanized | 国药准字H202341882mg | — | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563174mg | — | Official source ↗ |
| Hangzhou Minsheng Pharmaceutical Co., Ltd | 国药准字H20255470See source | — | Official source ↗ |
| Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized | 国药准字H202564332mg | — | Official source ↗ |
| Jiangsu Deyuan Pharmaceutical Co.,Ltd. | 国药准字H202642452mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20190039See source | — | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563174mg | — | Official source ↗ |
| Jiangsu Deyuan Pharmaceutical Co.,Ltd. | 国药准字H202642452mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20190039See source | — | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563174mg | — | Official source ↗ |
| Jiangsu Deyuan Pharmaceutical Co.,Ltd. | 国药准字H202642452mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20190039See source | — | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | — | Official source ↗ |
| Jiangsu Deyuan Pharmaceutical Co.,Ltd. | 国药准字H202642452mg | — | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | — | Official source ↗ |
| Jiangsu Deyuan Pharmaceutical Co.,Ltd. | 国药准字H202642452mg | — | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | — | Official source ↗ |
| Shandong Hua Bo Kai Sheng Bio Technology Co., Ltd. romanized | 国药准字H20256060See source | — | Official source ↗ |
| Guangzhou Lv Shi Zi Pharmaceutical Co., Ltd. romanized | 国药准字H202648892mg | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563182mg | — | Official source ↗ |
| Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized | 国药准字H202564324mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20215001See source | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563182mg | — | Official source ↗ |
| Hunan Qian Jin Xiang Jiang Pharma Co., Ltd. romanized | 国药准字H202564324mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20215001See source | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563182mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20215001See source | — | Official source ↗ |
| Fu Xing Wan Bang (Jiangsu) Pharmaceuticals Group Co., Ltd. romanized | 国药准字H202563182mg | — | Official source ↗ |
| Eli Lilly Nederland B.V. | 国药准字HJ20215001See source | — | Official source ↗ |
Under review 32
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Jiangsu Vanguard Pharmaceutical Co., Ltd. | CYHS2502940 | 2025/08/13 | Official source ↗ |
| Jiangsu Vanguard Pharmaceutical Co., Ltd. | CYHS2502939 | 2025/08/13 | Official source ↗ |
| Shandong Lu Kang Pharmaceuticals Group Sai Te Co., Ltd. romanized; Jiangsu Hua Yang Pharmaceutical Co., Ltd. romanized | CYHS2502558 | 2025/07/16 | Official source ↗ |
| Hubei Min Kang Pharmaceutical Co., Ltd. romanized; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2602396 | 2026/09/23 | Official source ↗ |
| Hubei Min Kang Pharmaceutical Co., Ltd. romanized; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2602395 | 2026/09/23 | Official source ↗ |
| NANJING ZENKOM PHARMACEUTICAL CO.,LTD. | CYHS2504312 | 2025/12/19 | Official source ↗ |
| Jiangsu Shen Hua Pharma Co., Ltd. romanized | CYHS2601782 | 2026/07/24 | Official source ↗ |
| Shandong Liang Fu Pharmaceutical Co., Ltd. romanized | CYHS2602588 | 2026/10/21 | Official source ↗ |
| Sichuan Xin Si Dun Pharmaceutical Co., Ltd. romanized | CYHS2602386 | 2026/09/22 | Official source ↗ |
| Shanghai Shang Yao Zhong Xi Pharmaceutical Co., Ltd. romanized | CYHS2602021 | 2026/08/14 | Official source ↗ |
| Anhui Bei Ke Biopharmaceutical Co., Ltd. romanized | CYHS2601730 | 2026/07/20 | Official source ↗ |
| Anhui Bei Ke Biopharmaceutical Co., Ltd. romanized | CYHS2601729 | 2026/07/20 | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | CYHS2601701 | 2026/07/16 | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | CYHS2601700 | 2026/07/16 | Official source ↗ |
| Guangzhou Da Guang Pharmaceutical Co., Ltd. romanized | CYHS2601466 | 2026/06/23 | Official source ↗ |
| Shandong Bai Nuo Pharmaceuticals Co., Ltd. romanized; Dong Wu Pharmaceutical (Shandong) Co., Ltd. romanized | CYHS2601102 | 2026/05/13 | Official source ↗ |
| Shandong Bai Nuo Pharmaceuticals Co., Ltd. romanized; Dong Wu Pharmaceutical (Shandong) Co., Ltd. romanized | CYHS2601101 | 2026/05/13 | Official source ↗ |
| Anhui Tai En Kang Pharmaceutical Co., Ltd. romanized | CYHS2600935 | 2026/04/23 | Official source ↗ |
| Shandong Lang Nuo Pharmaceutical Co., Ltd. romanized | CYHS2600723 | 2026/03/26 | Official source ↗ |
| Shandong Lang Nuo Pharmaceutical Co., Ltd. romanized | CYHS2600722 | 2026/03/26 | Official source ↗ |
| MSN LABORATORIES PRIVATE LIMITED | JYHS2600005 | 2026/03/02 | Official source ↗ |
| MSN LABORATORIES PRIVATE LIMITED | JYHS2600004 | 2026/03/02 | Official source ↗ |
| Jiangxi Di Sai Nuo Pharmaceuticals Group Co., Ltd. romanized | CYHS2600566 | 2026/02/27 | Official source ↗ |
| Zhejiang Dong Ya Pharma Co., Ltd. romanized | CYHS2600397 | 2026/02/06 | Official source ↗ |
| Ningbo Menovo Tiankang Pharmaceutical Co., Ltd. | CYHS2600139 | 2026/01/10 | Official source ↗ |
| Ningbo Menovo Tiankang Pharmaceutical Co., Ltd. | CYHS2600138 | 2026/01/10 | Official source ↗ |
| Beijing Foyou Pharma CO.,LTD | CYHS2600012 | 2026/01/05 | Official source ↗ |
| Hainan Hai Ling Chemical Pharmaceutical Co., Ltd. romanized | CYHS2504339 | 2025/12/22 | Official source ↗ |
| Hainan Hai Ling Chemical Pharmaceutical Co., Ltd. romanized | CYHS2504338 | 2025/12/22 | Official source ↗ |
| Tian Di Heng Yi Pharmaceutical Co., Ltd. romanized | CYHS2503843 | 2025/10/31 | Official source ↗ |
| ZHE JIANG HUA HAI PHARMACEUTICALCO.,LTD. | CYHS2502962 | 2025/08/13 | Official source ↗ |
| Hai Hua Sheng Ming (Xiamen) Technology Co., Ltd. romanized; Hua Yi Tai Kang Pharma Co., Ltd. romanized | CYHS2502477 | 2025/07/11 | Official source ↗ |
Generic-filing companies this year 15
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Hubei Min Kang Pharmaceutical Co., Ltd. romanized; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2602396 | 2026/09/23 | Official source ↗ |
| Hubei Min Kang Pharmaceutical Co., Ltd. romanized; Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | CYHS2602395 | 2026/09/23 | Official source ↗ |
| Jiangsu Shen Hua Pharma Co., Ltd. romanized | CYHS2601782 | 2026/07/24 | Official source ↗ |
| Shandong Liang Fu Pharmaceutical Co., Ltd. romanized | CYHS2602588 | 2026/10/21 | Official source ↗ |
| Sichuan Xin Si Dun Pharmaceutical Co., Ltd. romanized | CYHS2602386 | 2026/09/22 | Official source ↗ |
| Shanghai Shang Yao Zhong Xi Pharmaceutical Co., Ltd. romanized | CYHS2602021 | 2026/08/14 | Official source ↗ |
| Anhui Bei Ke Biopharmaceutical Co., Ltd. romanized | CYHS2601730 | 2026/07/20 | Official source ↗ |
| Anhui Bei Ke Biopharmaceutical Co., Ltd. romanized | CYHS2601729 | 2026/07/20 | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | CYHS2601701 | 2026/07/16 | Official source ↗ |
| CISEN PHARMACEUTICAL CO., LTD. | CYHS2601700 | 2026/07/16 | Official source ↗ |
| Guangzhou Da Guang Pharmaceutical Co., Ltd. romanized | CYHS2601466 | 2026/06/23 | Official source ↗ |
| Shandong Bai Nuo Pharmaceuticals Co., Ltd. romanized; Dong Wu Pharmaceutical (Shandong) Co., Ltd. romanized | CYHS2601102 | 2026/05/13 | Official source ↗ |
| Shandong Bai Nuo Pharmaceuticals Co., Ltd. romanized; Dong Wu Pharmaceutical (Shandong) Co., Ltd. romanized | CYHS2601101 | 2026/05/13 | Official source ↗ |
| Anhui Tai En Kang Pharmaceutical Co., Ltd. romanized | CYHS2600935 | 2026/04/23 | Official source ↗ |
| Shandong Lang Nuo Pharmaceutical Co., Ltd. romanized | CYHS2600723 | 2026/03/26 | Official source ↗ |
| Shandong Lang Nuo Pharmaceutical Co., Ltd. romanized | CYHS2600722 | 2026/03/26 | Official source ↗ |
| Jiangxi Di Sai Nuo Pharmaceuticals Group Co., Ltd. romanized | CYHS2600566 | 2026/02/27 | Official source ↗ |
| Zhejiang Dong Ya Pharma Co., Ltd. romanized | CYHS2600397 | 2026/02/06 | Official source ↗ |
| Ningbo Menovo Tiankang Pharmaceutical Co., Ltd. | CYHS2600139 | 2026/01/10 | Official source ↗ |
| Ningbo Menovo Tiankang Pharmaceutical Co., Ltd. | CYHS2600138 | 2026/01/10 | Official source ↗ |
| Beijing Foyou Pharma CO.,LTD | CYHS2600012 | 2026/01/05 | Official source ↗ |
API companies with A status 7
| Company (original) | Identifier (original) | Source date | Official source |
|---|---|---|---|
| Fujian Nan Fang Pharmaceutical Co., Ltd. romanized | Y20230000885 | 2026/03/26 | Official source ↗ |
| Xu Zhou Wan Bang Jin Qiao Pharmaceutical Co., Ltd. romanized | Y20240000287 | 2025/12/25 | Official source ↗ |
| Nanjing Hai Na Pharmaceutical Co., Ltd. romanized | Y20240000293 | 2026/02/13 | Official source ↗ |
| Tian Di Heng Yi Pharmaceutical Co., Ltd. romanized | Y20240000146 | 2026/07/16 | Official source ↗ |
| Guangzhou Lv Shi Zi Pharmaceutical Co., Ltd. romanized | Y20230000965 | 2026/05/20 | Official source ↗ |
| Natco Pharma Limited | Y20230000557 | 2025/12/17 | Official source ↗ |
| Nanjing Li Bo Wei Pharmaceutical Co., Ltd. romanized | Y20210000460 | 2024/05/16 | Official source ↗ |
Trial registrations 2025/2026 —
Not loaded
Sources and dates
- FDA Orange Book
- 2026/11/06
- CDE acceptance and review
- 2026/11/13 06:42
- Chemical Drug Catalog
- 2026/11/13 06:39
- API registration records
- 2026/11/13 06:41
- NHSA drug code database
- 2026/10/23
- Trial registry
- 2026/11/13 08:09 · Incomplete coverage
Chinese counts use complete ingredient, dosage-form and route matches. Unmatched and partial rows show name-source matching only and make no finding about Chinese approvals or filings. Trials cover registration-number years 2025/2026 only.
Comparison generated: 2026/11/13 18:41 · openFDA Orange Book ↗
Name and dosage-form matching sources
- CDE chemical-drug catalogue detail ↗ · idCode=149c9570d4647b922df982547bf6cb63
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Sign in to subscribeYearly
US$1,920
Billed every year
US$160 per month
Sign in to subscribeNeed more than 10 followed products or more than 5 recipients? Contact us.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
Billed by Creem, our merchant of record · Terms · Refund policy